10,000 Shares in Kura Oncology, Inc. (NASDAQ:KURA) Purchased by Harbor Advisors LLC

Harbor Advisors LLC purchased a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA) during the fourth quarter, Holdings Channel reports. The firm purchased 10,000 shares of the company’s stock, valued at approximately $87,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Point72 DIFC Ltd acquired a new position in Kura Oncology in the 3rd quarter valued at about $146,000. E Fund Management Co. Ltd. acquired a new position in Kura Oncology in the 4th quarter valued at about $90,000. Erste Asset Management GmbH acquired a new position in Kura Oncology in the 3rd quarter valued at about $215,000. Corient Private Wealth LLC acquired a new position in Kura Oncology in the 4th quarter valued at about $109,000. Finally, Bellevue Group AG boosted its holdings in Kura Oncology by 36.0% in the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after purchasing an additional 3,600 shares during the last quarter.

Kura Oncology Price Performance

Shares of KURA opened at $7.84 on Friday. Kura Oncology, Inc. has a fifty-two week low of $6.79 and a fifty-two week high of $23.48. The firm’s 50 day moving average price is $7.82 and its 200 day moving average price is $12.43. The company has a market cap of $633.12 million, a P/E ratio of -3.32 and a beta of 0.85. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million. On average, research analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on KURA. BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. Scotiabank decreased their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. JMP Securities restated a “market outperform” rating and issued a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $25.50.

Insider Buying and Selling at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,729 shares of company stock valued at $92,307. Insiders own 5.50% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.